Lansoprazole

When ATH:
A02BC03

Characteristic.

The substituted benzimidazole derivative. Whitish-brown granular powder;. Sparingly soluble in ethyl alcohol, insoluble in hexane and water. Resistant to light, at 25 ° C decomposes in an acidic medium with T1/2 0,5 h at pH 5,0 and 18 h - at pH 7,0.

Pharmacological action.
Antiulcer.

Application.

Neyazvennaya dyspepsia, gastric ulcer and duodenal ulcer, benign gastric ulcer, erosive and ulcerative esophagitis, reflux esophagitis, Zollinger - Ellison, infection Helicobacter pylori (combination therapy).

Contraindications.

Hypersensitivity, malignant neoplasms of the gastrointestinal tract, pregnancy (especially I trimester), lactation.

Restrictions apply.

Abnormal liver function, Age to 18 years (safety and effectiveness in these patients has been poorly studied), advanced age.

Pregnancy and breast-feeding.

I contraindicated in I trimester. Во II и III триместрах возможно, if the expected benefit of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.

Side effects.

From the digestive tract: diarrhea; less often - increase or decrease of appetite, nausea, stomach ache; rarely - constipation; in some cases - ulcerative colitis, gastrointestinal candidiasis, increase in liver enzymes (GOLD, IS, Alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase) and bilirubin.

From the nervous system and sensory organs: headache; rarely - a feeling of malaise, dizziness, drowsiness, depression, alarm.

From the respiratory system: rarely - a strong cough, pharyngitis, rhinitis, inflammation or infection of the upper respiratory tract.

Cardio-vascular system and blood: seldom-B19 (with hemorrhagic manifestations); in some cases - anemia.

For the skin: in some cases, photosensitization, erythema multiforme, alopecia.

Allergic reactions: skin rash.

Other: rarely - flu-like symptoms, myalgia.

Cooperation.

Decreases (on 10%) theophylline clearance. Sukralyfat of 30% reduces the bioavailability of (It should be an interval of 30-40 minutes between doses of these drugs). Antacids, containing magnesium hydroxide and algeldrat, while admission to lansoprazole may reduce the absorption of the latter. It can change the pH-dependent absorption of drugs, belonging to the groups of weak acids (slowdown) and bases (acceleration). It inhibits the absorption of ampicillin, digoksina, ketoconazole, цianokoʙalamina, iron salts. Possible interactions with drugs, metabolized with participation of cytochrome P450 enzyme system. Compatible with antipyrine, diazepamom, ibuprofen, Indomethacin, oral contraceptives, phenytoin, prednisolone, propranolol, varfarinom.

Overdose.

Symptoms: not disclosed (receiving a single dose 600 mg was not accompanied by clinical signs of overdose).

Treatment: recommended monitoring, carrying out maintenance and symptomatic therapy. Hemodialysis nyeeffyektivyen.

Dosing and Administration.

Inside, morning. Neyazvennaya dyspepsia: 15-30 mg / day for 2-4 weeks. Duodenal ulcer: 30 mg / day for 2-4 weeks. Gastric ulcer: 30-60 mg / day for 4-8 weeks. Erosive and ulcerative esophagitis: 30-60 mg / day for 4-8 weeks. Reflux esophagitis: 30 mg/day — 4 Sun. Zollinger - Ellison: Adjusted-dose, provides a level of acid below the basal 10 mmol / h. Инфицирование Helicobacter pylori: by 30 mg 2 times a day in the various schemes of the combined therapy of H. pylori.

Precautions.

Before and after the treatment required endoscopic examinations to exclude malignancies (lansoprazole can mask the symptoms and delay diagnosis). To use caution in patients with reduced liver function and in elderly patients (treatment is initiated with half doses, gradually increasing them to the recommended, but not more 30 mg / day). While the use of antacids should be used for their 1 hours before or after 1-2 h after administration of lansoprazole.

Cooperation

Active substanceDescription of interaction
Algeldrat + Magnesium hydroxideFKV. Slows absorption (the interval between doses should be at least 2 no).
AmoksiцillinFMR. Increases (mutually) the risk of side effects from the gastrointestinal tract (glossitis, stomatitis, melanoglossiya).
AmpicillinFKV. Against the background of lansoprazole (lowers the pH of gastric contents) slows absorption.
WarfarinDo not change (mutually) effect; permissible combined use.
DiazepamDo not change (mutually) effect; permissible combined use.
DigoxinFKV. Against the background of lansoprazole (lowers the pH of gastric contents) slows absorption.
Ferrous gluconateFKV. Against the background of lansoprazole (increases the gastric pH) reduced absorption.
Iron fumarateFKV. Against the background of lansoprazole (increases the gastric pH) reduced absorption.
IbuprofenAgainst the background of lansoprazole reduced the risk of gastric mucosa.
IndomethacinAgainst the background of lansoprazole reduced the risk of gastric mucosa.
KetoconazoleFKV. Against the background of lansoprazole (lowers the pH of gastric contents) slows absorption.
PrednisoloneFMR. Against the background of lansoprazole reduced the risk of gastric mucosa.
PropranololDo not change (mutually) effect; permissible combined use.
SucralfateFKV. Decreases (on 30%) bioavailability; with a joint appointment interval between doses should be 30-40 minutes.
TheophyllineFKV. Against the background of some of lansoprazole (on 10%) reduced clearance.
PhenytoinDo not change (mutually) effect; permissible combined use.
ЦianokoʙalaminFKV. Against the backdrop of slowing down the absorption of lansoprazole.

Back to top button